newsfilter
← Latest News
GlobeNewswire·

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose levelPositive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced MSA as observed in